Petzke, Frank

[["dc.bibliographiccitation.firstpage","732"],["dc.bibliographiccitation.issue","43"],["dc.bibliographiccitation.journal","DEUTSCHES ARZTEBLATT INTERNATIONAL"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","111"],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Bock, Fritjof"],["dc.contributor.author","Engeser, Peter"],["dc.contributor.author","Toelle, Thomas"],["dc.contributor.author","Willweber-Strumpf, Anne"],["dc.contributor.author","Petzke, Frank"],["dc.date.accessioned","2018-11-07T09:33:24Z"],["dc.date.available","2018-11-07T09:33:24Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: The long-term use of opioid analgesic drugs to treat chronic non-cancer pain (CNCP) is a major component of pain pharmacotherapy. The interpretation of the evidence concerning its efficacy and risks is currently debated. Methods: An interdisciplinary evidence-and consensus-based S3 guideline was updated on the basis of a systematic literature search (CENTRAL, Medline, and Scopus databases, from October 2008 to October 2013); meta-analyses of randomized controlled trials (>= 4 weeks); and a consensus procedure, as specified by the AWMF regulations, including 22 medical and psychological societies and 2 patient self-help organizations. Results: 119 publications were used to update the guideline, and 6 systematic reviews with meta-analyses were performed. A nominal group process was used to formulate recommendations concerning the indications and contra indications for the treatment of CNCP with opioid analgesics and the manner in which such treatments should be carried out. Opioid analgesics are an option for the short-term treatment (4-12 weeks) of chronic pain due to osteoarthritis (pain intensity, standardized mean difference [ SMD]: -0.22 and -0.26), diabetic polyneuropathy (SMD -0.74), post-herpetic neuralgia (SMD -0.58), and chronic low back pain (SMD: -0.29 and -0.74). Long-term opioid treatment (>= 26 weeks) for these diseases benefits only about 25% of patients. For other conditions, either short- or long-term treatment with opioid analgesics should be considered an individual therapeutic trial. Opioid treatment for pain is contraindicated by primary headaches and by any functional or mental disorder of which pain is a leading manifestation. Conclusion: To minimize the risks of opioid analgesic treatment, physicians must be aware of its contraindications and must regularly reassess its efficacy and side effects. Pharmacotherapy should be combined with other types of treatment."],["dc.description.sponsorship","Mundipharma company; Grunenthal company; Janssen-Cilag; Pfizer"],["dc.identifier.doi","10.3238/arztebl.2014.0732"],["dc.identifier.isi","000344902900002"],["dc.identifier.pmid","25404530"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31957"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Deutscher Aerzte-verlag Gmbh"],["dc.relation.issn","1866-0452"],["dc.title","Long-Term Opioid Use in Non-Cancer Pain"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","72"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Welsch, P."],["dc.contributor.author","Klose, P."],["dc.contributor.author","Schaefert, R."],["dc.contributor.author","Sommer, C."],["dc.contributor.author","Haeuser, Winfried"],["dc.date.accessioned","2018-11-07T10:01:21Z"],["dc.date.available","2018-11-07T10:01:21Z"],["dc.date.issued","2015"],["dc.description.abstract","The efficacy and safety of opioid therapy in chronic low back pain (CLBP) is under debate. We updated a recent systematic review on the efficacy and safety of opioids in CLBP. We screened MEDLINE, Scopus and the Cochrane Central Register of Controlled Trials (CENTRAL) up until October 2013, as well as reference sections of original studies and systematic reviews of randomized controlled trials (RCTs) of opioids in CLBP. We included double-blind randomized placebo-controlled studies of at least 4 weeks duration. Using a random effects model, absolute risk differences (RD) were calculated for categorical data and standardized mean differences (SMD) for continuous variables. We included 12 RCTs with 17 treatment arms and 4375 participants. Median study duration was 12 (4-16) weeks. Of the 17 treatment arms, seven (41.2 %) used oxycodone; four (23.6 %) tramadol; buprenorphine and oxymorphone were each used in two (11.8 %) and hydromorphone and tapentadol each in one (5.8 %). The results for studies with parallel/cross-over design were as follows (with 95 % confidence interval, CI): opioids were superior to placebo in reducing pain intensity (SMD -aEuro parts per thousand 0.29 [-aEuro parts per thousand 0.37, -aEuro parts per thousand 0.21], p < 0.0001; six studies with 2896 participants). Opioids were superior to placebo in 50 % pain reduction (RD 0.05 [0.01, 0.10], p = 0.01; two studies with 1492 participants; number needed to benefit (NNTB) 19 [95 % CI 10-107]). Opioids were not superior to placebo in reports of much or very much improved pain (RD 0.16 [-aEuro parts per thousand 0.01, 0.34], p = 0.07; two studies with 1153 participants). Opioids were superior to placebo in improving physical functioning (SMD -aEuro parts per thousand 0.22 [-aEuro parts per thousand 0.31, -aEuro parts per thousand 0.12], p < 0.0001; four studies with 1895 participants). Patients dropped out less frequently with opioids than with placebo due to lack of efficacy (RD -aEuro parts per thousand 0.10 [-aEuro parts per thousand 0.16, -aEuro parts per thousand 0.04], p = 0.001; five studies with 3168 participants; NNTB 10 [8-13]). Patients dropped out more frequently with opioids than with placebo due to adverse events (RD 0.12 [0.05, 0.19], p = 0.0007; six studies with 2910 participants; number needed to harm (NNTH) 7 [95 % CI 6-8]). There was no significant difference between opioids and placebo in terms of the frequency of serious adverse events or deaths. Opioids were superior to placebo in terms of efficacy and inferior in terms of tolerability. Opioids and placebo did not differ in terms of safety during the study period. The conclusion on the safety of opioids compared to placebo is limited by the low number of serious adverse events and deaths. Short-term and intermediate-term opioid therapy may be considered in selected CLBP patients. The English full-text version of this article is freely available at SpringerLink (under \"Supplemental\")."],["dc.identifier.doi","10.1007/s00482-014-1449-8"],["dc.identifier.isi","000350037700005"],["dc.identifier.pmid","25503883"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37998"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-2129"],["dc.relation.issn","0932-433X"],["dc.title","Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","197"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","199"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Kuehn, E."],["dc.contributor.author","Wolf, B."],["dc.contributor.author","Nothacker, M."],["dc.contributor.author","Petzke, Frank"],["dc.date.accessioned","2018-11-07T10:23:08Z"],["dc.date.available","2018-11-07T10:23:08Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00482-017-0219-9"],["dc.identifier.isi","000402959300001"],["dc.identifier.pmid","28493222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42400"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-2129"],["dc.relation.issn","0932-433X"],["dc.title","Twelve years of the S3 guideline Fibromyalgia Syndrome-a never-ending war?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","259"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","267"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Sommer, C."],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Burgmer, Markus"],["dc.contributor.author","Engelhardt, R."],["dc.contributor.author","Gerhold, K."],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Schmidt-Wilcke, Tobias"],["dc.contributor.author","Spaeth, Martin A."],["dc.contributor.author","Toelle, Thomas"],["dc.contributor.author","Ueceyler, N."],["dc.contributor.author","Wang, H."],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Thieme, Kirsten M."],["dc.date.accessioned","2018-11-07T09:09:32Z"],["dc.date.available","2018-11-07T09:09:32Z"],["dc.date.issued","2012"],["dc.description.abstract","The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies (\"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften\", AWMF; registration number 041/004) was planned starting in March 2011. The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy (\"Deutsche Interdisziplinaren Vereinigung fur Schmerztherapie\", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. Current data do not identify distinct etiologic or pathophysiological factors mediating development of FMS. The development of FMS is associated with inflammatory rheumatic diseases (EL2b), with gene polymorphisms of the 5-hydroxytryptamine (HT)(2) receptor (EL3a), lifestyle factors (smoking, obesity, lack of physical activity; EL2b), physical and sexual abuse in childhood and adulthood (EL3a). FMS is most likely the result of various pathogenetic factors and pathophysiological mechanisms. The English full-text version of this article is available at SpringerLink (under \"Supplemental\")."],["dc.identifier.doi","10.1007/s00482-012-1174-0"],["dc.identifier.isi","000306065900004"],["dc.identifier.pmid","22760458"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26285"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0932-433X"],["dc.title","Etiology and pathophysiology of fibromyalgia syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","247"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","258"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Eich, W."],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Arnold, Bernhard"],["dc.contributor.author","Jaeckel, W."],["dc.contributor.author","Offenbaecher, M."],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Schiltenwolf, M."],["dc.contributor.author","Settan, M."],["dc.contributor.author","Sommer, C."],["dc.contributor.author","Toelle, Thomas"],["dc.contributor.author","Ueceyler, N."],["dc.contributor.author","Henningsen, P."],["dc.date.accessioned","2018-11-07T09:09:31Z"],["dc.date.available","2018-11-07T09:09:31Z"],["dc.date.issued","2012"],["dc.description.abstract","The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies (\"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften\", AWMF; registration number 041/004) was planned starting in March 2011. The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy (\"Deutsche Interdisziplinaren Vereinigung fur Schmerztherapie\", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. The formulation and grading of recommendations was accomplished using a multi-step, formal consensus process. The guidelines were reviewed by the boards of the participating scientific medical societies. The clinical diagnosis of FMS can be established by the American College of Rheumatology (ACR) 1990 classification criteria (with tender point examination), by the modified preliminary diagnostic ACR 2010 criteria or by the diagnostic criteria of the German interdisciplinary guideline (AWMF) on FMS. The English full-text version of this article is available at SpringerLink (under \"Supplemental\")."],["dc.identifier.doi","10.1007/s00482-012-1169-x"],["dc.identifier.isi","000306065900003"],["dc.identifier.pmid","22760457"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26284"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0932-433X"],["dc.title","Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","128"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Krasselt, M."],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Baerwald, C."],["dc.date.accessioned","2018-11-07T10:17:36Z"],["dc.date.available","2018-11-07T10:17:36Z"],["dc.date.issued","2016"],["dc.description.abstract","The long-term use of opioids for chronic pain can be problematic in many respects. Besides potentially harmful and considerable undesired side effects and possible drug abuse, the indications for prescription, efficacy and safety in the long run have to be considered. The recently updated S3 guidelines on long-term opioid treatment in non-cancer pain (LONTS) provide recommendations with the highest currently available evidence. This article summarizes the most relevant contents for the clinical rheumatologist."],["dc.identifier.doi","10.1007/s00393-015-1686-y"],["dc.identifier.isi","000372299600004"],["dc.identifier.pmid","26558623"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41260"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1435-1250"],["dc.relation.issn","0340-1855"],["dc.title","S3 guidelines on long-term opioid treatment in non-cancer pain. Recommendations for opioid use in clinical rheumatology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","274"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","283"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Sommer, C."],["dc.contributor.author","Alten, R."],["dc.contributor.author","Baer, K.-J."],["dc.contributor.author","Bernateck, M."],["dc.contributor.author","Brueckle, W."],["dc.contributor.author","Friedel, E."],["dc.contributor.author","Henningsen, P."],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Toelle, Thomas"],["dc.contributor.author","Ueceyler, N."],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Haeuser, Winfried"],["dc.date.accessioned","2018-11-07T10:23:10Z"],["dc.date.available","2018-11-07T10:23:10Z"],["dc.date.issued","2017"],["dc.description.abstract","The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017. The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n =8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A literature search for systematic reviews of randomized controlled drug trials from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. Amitriptyline and duloxetine are recommended in the case of comorbid depressive disorders or generalized anxiety disorder and pregabalin in the case of generalized anxiety disorder. Off-label use of duloxetine and pregabalin can be considered if there are no comorbid mental disorders or no generalized anxiety disorder. Strong opioids are not recommended."],["dc.identifier.doi","10.1007/s00482-017-0207-0"],["dc.identifier.isi","000402959300008"],["dc.identifier.pmid","28493231"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42405"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-2129"],["dc.relation.issn","0932-433X"],["dc.title","Drug therapy of fibromyalgia syndrome. Updated guidelines 2017 and overview of systematic review articles"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","246"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","254"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Brueckle, W."],["dc.contributor.author","Eidmann, U."],["dc.contributor.author","Heldmann, P."],["dc.contributor.author","Koellner, Volker"],["dc.contributor.author","Kuehn, T."],["dc.contributor.author","Kuehn-Becker, H."],["dc.contributor.author","Strunk-Richter, M."],["dc.contributor.author","Schiltenwolf, M."],["dc.contributor.author","Settan, M."],["dc.contributor.author","von Wachter, M."],["dc.contributor.author","Weigl, Martin"],["dc.contributor.author","Haeuser, Winfried"],["dc.date.accessioned","2018-11-07T10:23:10Z"],["dc.date.available","2018-11-07T10:23:10Z"],["dc.date.issued","2017"],["dc.description.abstract","The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017. The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n =8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A search of the literature for systematic reviews on randomized, controlled trials on patient education and shared decision-making from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences, clinical and practical applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. The diagnosis of fibromyalgia syndrome should be explicitly communicated to the affected individual. Shared decision-making with the patient on the therapeutic options based on individual preferences of the patient, comorbidities and the success of previous treatment is recommended. A step-wise treatment approach depending on the severity of fibromyalgia syndrome and the response to therapeutic measures is recommended."],["dc.identifier.doi","10.1007/s00482-017-0201-6"],["dc.identifier.isi","000402959300005"],["dc.identifier.pmid","28493229"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42404"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-2129"],["dc.relation.issn","0932-433X"],["dc.title","General treatment principles, coordination of care and patient education in fibromyalgia syndrome Updated guidelines 2017 and overview of systematic review articles"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","297"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","310"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Sommer, C."],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Alten, R."],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Spaeth, Martin A."],["dc.contributor.author","Toelle, Thomas"],["dc.contributor.author","Ueceyler, N."],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Winter, E."],["dc.contributor.author","Baer, K. J."],["dc.date.accessioned","2018-11-07T09:09:33Z"],["dc.date.available","2018-11-07T09:09:33Z"],["dc.date.issued","2012"],["dc.description.abstract","The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies (\"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften\", AWMF; registration number 041/004) was planned starting in March 2011. The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy (\"Deutsche Interdisziplinaren Vereinigung fur Schmerztherapie\", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. The recommendations were based on level of evidence, efficacy (meta-analysis of the outcomes pain, sleep, fatigue and health-related quality of life), acceptability (total dropout rate), risks (adverse events) and applicability of treatment modalities in the German health care system. The formulation and grading of recommendations was accomplished using a multi-step, formal consensus process. The guidelines were reviewed by the boards of the participating scientific medical societies. Amitriptyline and-in case of comorbid depressive disorder or generalized anxiety disorder-duloxetine are recommended. Off-label use of duloxetine and pregabalin can be considered in case of no comorbid mental disorder. Strong opioids are not recommended. The English full-text version of this article is available at SpringerLink (under \"Supplemental\")."],["dc.identifier.doi","10.1007/s00482-012-1172-2"],["dc.identifier.isi","000306065900009"],["dc.identifier.pmid","22760463"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26290"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-2129"],["dc.relation.issn","0932-433X"],["dc.title","Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Haeuser, Winfried"],["dc.contributor.author","Klose, P."],["dc.contributor.author","Welsch, P."],["dc.contributor.author","Petzke, Frank"],["dc.contributor.author","Nothacker, M."],["dc.contributor.author","Kopp, I."],["dc.date.accessioned","2018-11-07T09:55:14Z"],["dc.date.available","2018-11-07T09:55:14Z"],["dc.date.issued","2015"],["dc.format.extent","312"],["dc.identifier.doi","10.1007/s00482-015-0009-1"],["dc.identifier.isi","000357432700010"],["dc.identifier.pmid","26022431"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36699"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-2129"],["dc.relation.issn","0932-433X"],["dc.title","Methods Report of the updated Guideline \"Long Term Use of Opioids in non-tumor-related Pain - LONTS\" (vol 29, pg 8, 2015)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]